Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion.

J Neurol · 2025 · PMC12534265 · PMID 41107611

Europe PMC DOI

hedged sentence

0.0511

closest p · 1.0× alpha

0.0511

boldest claim

The sentences

did not reach statistical significancep = 0.0511so close (0.05 < p ≤ 0.1)

In RMS patients with a longer disease duration, ublituximab showed a numerical improvement in EDSS scores (− 0.10 versus 0.01), although this did not reach statistical significance ( p = 0.0511).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.